Luciano Juan R, an insider at Eli Lilly and Co (LLY), purchased 16,741 shares of the company on December 14, 2025, at a price of $1,062.19 per share. This transaction totaled $17.78 million. Following this purchase, he holds a total of 16,741 shares in the company.
Eli Lilly, headquartered in Indianapolis, Indiana, engages in the discovery, development, manufacture, and sale of pharmaceutical products. The company employs approximately 47,000 people and operates in various segments, including cardiometabolic health, oncology, immunology, and neuroscience. Notable products include Humalog, Trulicity, and Jardiance.
With a market cap of $1,004.2 billion, Eli Lilly's P/E ratio stands at 54.54, and it boasts a dividend yield of 65.1%. Upcoming earnings are scheduled for April 29, 2026, with an estimated EPS of $7.62 and revenue of $17.5 billion, followed by another report on August 5, 2026, where EPS is expected to reach $8.18 on revenue of $18.9 billion.
Insider buying can signal confidence in a company's future, as executives often have access to non-public information. However, investors should consider these transactions as part of a broader analysis, looking at patterns across multiple insiders and time periods rather than isolated events. Transparency in insider activities is mandated by the SEC, providing valuable insights into executive sentiment regarding their company's stock.